Healthcare Systems

PhRMA has sued HHS and CMS over the GLOBE rule, arguing the agency has no authority to tie Medicare Part B drug payments to the prices paid in 19 other countries. The complaint leans on the major questions doctrine and a statutory ban on quality-adjusted life years. #SyenzaNews #MarketAccess #pharmaceuticals #healthcarepolicy #drugpricing

Lundbeck is trading scale for depth. Michala Fischer-Hansen, EVP for Europe and international markets, explains why 51 affiliates became 22, why a fifth of revenue now goes to R&D, and why US price pressure can decide where a medicine launches. #SyenzaNews #MarketAccess #brainhealth #pharma

US group health plans and issuers must rebuild their public price files under the Transparency in Coverage final rule: quarterly publication, an 11-claim threshold for out-of-network data, a new utilization file and attestation, and consumer phone disclosure from January 2027. #SyenzaNews #MarketAccess #PriceTransparency #HEOR

Alec Morton of NUS explains how AI is changing health technology assessment, what stays human, and why cheaper analysis could mean more health economics.

CTS's Global Horizon panel brought four US operators to Montréal to explain why the US healthcare market rewards commercial readiness over good technology, and what founders can do about it. #SyenzaNews #MarketAccess #HealthTech

South Korea is putting AI at the centre of its healthcare agenda, pairing the new AI Basic Healthcare Strategy with a USD 30.4 billion biohealth export target. Vice Minister Lee Hyung Hoon sets out the vision in an interview with PharmaBoardroom. #SyenzaNews #SouthKorea #Biohealth #DigitalHealth #MarketAccess

Portuguese private health insurers cleared €1 billion in six months as premiums climbed 9.1% to €466 a year. #SyenzaNews #HealthInsurance #Portugal #MarketAccess

South Africa’s health department pushes back on claims that state tenders are hollowing out pharmaceutical manufacturing, arguing the sector’s real pressures are regulatory rather than the result of procurement decisions.

🔑 How is South Africa’s SEP adjustment safeguarding pharma supply security? The latest Single Exit Price adjustment seeks to balance affordability with manufacturer sustainability, helping to stabilise medicine availability amid economic pressures. Read the full analysis to see what it means for pricing, supply chains and market access. #SyenzaNews #pharmaceuticals #regulatoryaffairs #MarketAccess #healthcarepolicy

Is the US childhood vaccine schedule really out of step with peer nations? A new analysis finds it aligns closely with other developed countries in both the number and timing of recommended vaccines. Explore the full comparison and what it means for vaccine policy. #SyenzaNews #globalhealth #HealthcareInnovation #healthcarepolicy #innovation

Is tirzepatide delivering better value than semaglutide for patients and payers? A fresh analysis shows how tirzepatide can drive greater cost savings alongside improved health outcomes in obesity and type 2 diabetes management. Discover the key findings shaping treatment and reimbursement decisions. #SyenzaNews #pharmaceuticals #HealthEconomics #costeffectiveness

Portugal's INFARMED has blocked public funding for Datroway in breast cancer, citing insufficient added value.